SAN FRANCISCO, April 04, 2018 -- Hagens Berman Sobol Shapiro LLP alerts investors in Patterson Companies, Inc. (NASDAQ:PDCO) to the May 29, 2018 Lead Plaintiff deadline in the securities class action pending in the United States District Court for the District of Minnesota. If you purchased or otherwise acquired Patterson Companies securities between June 26, 2015 and February 28, 2018 and suffered losses contact Hagens Berman Sobol Shapiro LLP. For more information visit:
https://www.hbsslaw.com/cases/PDCO
or contact Reed Kathrein, who is leading the firm’s investigation, by calling 510-725-3000 or emailing
On February 12, 2018, the United States Federal Trade Commission (“FTC”) announced it sued Patterson Companies and two other dental supply companies for illegally conspiring to restrain competition for dental products in the United States.
More specifically, the FTC charges the Company: (a) illegally restrained price competition for dental products in the United States; (b) distorted prices and undermined the ability of independent dentists to obtain lower prices and discounts for dental products; (c) deprived independent dentists of the benefits of vigorous price and service competition among full-service, national dental distributors; (d) unreasonably reduced output of dental products to dental buying groups; and (e) eliminated or reduced the competitive bidding process for sales to these buying groups.
This news drove the price of Patterson Companies shares down $1.71, or about 5%, to close at $31.21 on February 13, 2018.
Then, on March 1, 2018, Defendants announced its Chief Financial Officer left her position effective immediately.
This news drove the price of Patterson Companies shares down $7.48, or about 23%, to close at $24.11 that day.
“Patterson Companies investors have suffered enormous losses,” said Hagens Berman partner Reed Kathrein. “We’re focused on Defendants’ statements to investors about the Company’s revenues and purported industry competition.”
Whistleblowers: Persons with non-public information regarding Patterson Companies should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 510-725-3000 or email [email protected].
About Hagens Berman
Hagens Berman is a national investor-rights law firm headquartered in Seattle, Washington with 70+ attorneys in 11 offices across the country. The Firm represents investors, whistleblowers, workers and consumers in complex litigation. More about the firm and its successes can be found at www.hbsslaw.com. For the latest news visit our newsroom or follow us on Twitter at @classactionlaw.
Contact:
Reed Kathrein, 510-725-3000


Boeing Stock Jumps as FAA Certifies 737 MAX-7 After Years of Regulatory Review
Apple Stock Slides 7% as Weak Sales Forecast Overshadows Quarterly Earnings Beat
Nike China Strategy to Lift Margins Despite $1 Billion Sales Hit, Bernstein Says
Palantir Stock Soars as AI Demand Drives Strong Q2 Earnings and Higher 2026 Outlook
Roblox Stock Drops 16% as Q3 Bookings Forecast Misses Expectations
Holcim Raises 2026 Outlook After Strong Q2 Earnings Beat
BYD July Global Vehicle Sales Rise 22% as Overseas Demand Surges
HSBC H1 Profit Jumps 23%, Announces $1 Billion Share Buyback and Reaffirms 2028 Targets
Toyota Raises FY2027 Outlook, Announces ¥1 Trillion Buyback Despite Q1 Profit Dip
Chery Invests $75 Million in KG Mobility to Expand Global Automotive Partnership
Trump Urges Exxon, Chevron to Cut Gas Prices After Record Oil Profits
Capital One Says AML Review Led to Closure of Trump Organization Accounts
Vast Eyes Hong Kong IPO as Chinese AI Unicorn Gains Momentum
T-Mobile Executives Reportedly Oppose $300 Billion Deutsche Telekom Merger
Alibaba Stock Jumps as Qwen 3.8-MAX AI Model Intensifies China's AI Race
AstraZeneca, Bristol Myers Squibb Explore Mega Merger Worth Nearly $400 Billion
Novo Nordisk Eyes Turnaround as Oral Wegovy Challenges Eli Lilly in Weight-Loss Drug Race 



